SB2028: Permitting development of opioid treatment program if part of clinical trial and approved by institutional review board
Legislative Summary
The purpose of this bill is to permit an opioid treatment program to be developed if part of a clinical trial, approved by an institutional review board. The bill sets forth the opioid treatment program services to be developed and provides for a set timeframe. The opioid treatment program is required to register with the Board of Pharmacy. The bill permits an advanced practice registered nurse participating in a clinical trial, approved by an institutional review board, to dispense medication for the timeframe approved in the clinical trial after registering with the Board of Pharmacy. The bill permits the advanced practice registered nurse participating in a clinical trial, approved by an institutional review board, to exceed a 3-day supply for the timeframe of the clinical trial, after registering with the Board of Medicine.
Bill History
Amendments
sb2028 hfa akers and winzenreid 10-8 _1
sb2028 hfa akers and winzenreid 10-8 _1
sb2028 hfat akers
sb2028 hfat akers
sb2028 hfat rohrbach _2
sb2028 hfat rohrbach _2
sb2028 hfa heckert 10-8 _3
sb2028 hfa heckert 10-8 _3
sb2028 hfat heckert
sb2028 hfat heckert
sb2028 hfa heckert 10-8 _2
sb2028 hfa heckert 10-8 _2
sb2028 hfat rohrbach 10-8
sb2028 hfat rohrbach 10-8
sb2028 hfa heckert 10-8 _1
sb2028 hfa heckert 10-8 _1
sb2028 hfa rohrbach 10-8 _1
sb2028 hfa rohrbach 10-8 _1
sb2028 hfa akers and winzenreid 10-8 _3
sb2028 hfa akers and winzenreid 10-8 _3
sb2028 hfa akers and winzenreid 10-8 _3 adopted
sb2028 hfa akers and winzenreid 10-8 _3 adopted
sb2028 hfa akers and winzenreid 10-8 _2
sb2028 hfa akers and winzenreid 10-8 _2
sb2028 hfat akers adopted
sb2028 hfat akers adopted
sb2028 hfa heckert 10-8 _3 adopted
sb2028 hfa heckert 10-8 _3 adopted